Gonadorelin: What the Research Actually Shows

A Comprehensive Evidence Review — GnRH Pulsatility, Hypogonadism, Fertility Induction, and the Pulse-vs-Continuous Paradox

Gonadorelin is synthetic gonadotropin-releasing hormone (GnRH) — a faithful copy of the endogenous decapeptide produced by neurons in the hypothalamic arcuate nucleus that governs the entire hypothalamic-pituitary-gonadal (HPG) axis. It is simultaneously one of the most physiologically fundamental peptides in reproductive endocrinology and one of the most pharmacologically counterintuitive compounds in all of medicine: the same molecule, administered differently, produces opposite effects. Given in brief pulses every 60–120 minutes — mimicking the endogenous pattern — it stimulates pituitary gonadotropin release and drives sex hormone production. Given continuously — flooding the pituitary receptors without the natural pulsatile rhythm — it causes profound gonadotropin suppression and sex hormone castration. This bidirectional pharmacology makes gonadorelin a critical diagnostic and therapeutic tool that is mechanistically distinct from its long-acting GnRH agonist relatives (leuprolide, triptorelin, nafarelin), which exploit the continuous-suppression pathway exclusively.

In clinical practice, gonadorelin occupies a specific and important niche: it is used for pulsatile stimulation of the HPG axis in conditions where the axis is intact but the hypothalamic GnRH pulse generator has failed. These include hypothalamic amenorrhea (one of the most common causes of infertility and absent menstruation in reproductive-age women), male hypogonadotropic hypogonadism (where testosterone deficiency results from GnRH or gonadotropin secretion failure rather than primary testicular failure), and fertility induction in both sexes where the pituitary is functional but not being driven. Gonadorelin is also used diagnostically — a single IV dose reliably tests pituitary gonadotroph reserve and GnRH responsiveness.

In the self-experimentation and men’s health community, gonadorelin has gained significant traction as a tool for maintaining testicular function and intratesticular testosterone production during exogenous testosterone therapy — a context entirely off-label but mechanistically grounded. When exogenous testosterone suppresses the HPG axis through negative feedback, the LH signal that normally drives testicular Leydig cell testosterone production disappears. Gonadorelin, delivered in pulses, replaces the hypothalamic GnRH signal and maintains the LH drive — preserving testicular size, function, and fertility potential during testosterone therapy. This use case has driven considerable research community interest in gonadorelin and distinguishes it from hCG, the traditional alternative, in several meaningful pharmacological ways.

What Is Gonadorelin?

Gonadorelin is the synthetic form of gonadotropin-releasing hormone (GnRH), a decapeptide hypothalamic neurohormone that serves as the master upstream regulator of reproductive endocrine function in all vertebrates. The endogenous molecule is produced by GnRH neurons in the arcuate nucleus and preoptic area of the hypothalamus and released in discrete pulses into the hypophyseal portal circulation — the specialized blood supply connecting the hypothalamus to the anterior pituitary gland. These pulses, arriving at the pituitary every 60–120 minutes in reproductive-age humans, maintain tonic stimulation of pituitary gonadotrophs, driving the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

LH and FSH in turn act on the gonads: LH stimulates Leydig cells in the testes to produce testosterone and granulosa/theca cells in the ovaries during the mid-cycle surge to trigger ovulation; FSH stimulates Sertoli cells in the testes (supporting spermatogenesis) and granulosa cells in the ovaries (supporting follicle development and estrogen production). The full cascade from hypothalamic GnRH pulse to gonadal sex hormone output constitutes the HPG axis — and gonadorelin, when administered in physiological pulses, drives the entire axis from its apex.

Synthetic gonadorelin is identical in sequence to endogenous GnRH: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. It has the same short half-life (2–4 minutes in circulation) and requires the same pulsatile delivery pattern to produce stimulation. This short half-life is pharmacologically significant: it means that sc or IV bolus injection produces a brief GnRH pulse that mimics the physiological pattern, whereas IV infusion or depot formulation would produce continuous receptor occupancy — and therefore the opposite, suppressive effect.

---

Origins and Discovery

The isolation and characterization of gonadotropin-releasing hormone is one of the great stories of modern endocrinology—a Nobel Prize-winning race between two competing laboratories that fundamentally changed our understanding of how the brain controls reproduction.

By the late 1960s, it was known that the hypothalamus produced a substance that triggered pituitary gonadotropin release, but no one had isolated or characterized it. Two groups—Andrew Schally’s laboratory at Tulane University in New Orleans and Roger Guillemin’s laboratory at the Salk Institute in La Jolla—raced to be first. The competition required processing extraordinary quantities of animal hypothalami: Schally’s group worked with pig hypothalami, Guillemin’s with sheep. Both teams ultimately needed hundreds of thousands of hypothalamic fragments to extract enough material for structural characterization. Schally’s group reached the finish line first, publishing the structure of porcine GnRH in 1971: pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH₂. Guillemin’s team confirmed an identical structure from ovine hypothalami shortly afterward. The decapeptide was initially called LHRH (luteinizing hormone-releasing hormone) before the name GnRH was adopted to reflect its ability to release both LH and FSH.

In 1977, Schally and Guillemin shared the Nobel Prize in Physiology or Medicine for their discoveries concerning peptide hormone production in the brain—along with Rosalyn Yalow for her development of radioimmunoassay, the technique that made measuring these tiny hormone quantities possible in the first place.

The clinical implications unfolded rapidly. Synthetic GnRH (gonadorelin) was produced almost immediately after the structure was known, and diagnostic use began in the mid-1970s. The critical breakthrough in understanding GnRH physiology came from Ernst Knobil’s laboratory at the University of Pittsburgh in the late 1970s and early 1980s. Working with rhesus monkeys whose hypothalamic GnRH neurons had been surgically destroyed, Knobil demonstrated that pulsatile GnRH delivery restored normal reproductive function, while continuous infusion of the same molecule suppressed it. This paradox—the same agonist producing opposite effects depending on delivery pattern—became the foundation for an entire class of therapeutics. The long-acting GnRH agonists (leuprolide, goserelin, triptorelin, nafarelin) were all developed specifically to exploit the continuous-suppression pathway that Knobil’s experiments had revealed.

Gonadorelin was approved by the FDA as Factrel (for diagnostic use) and later as Lutrepulse (for pulsatile fertility induction). Commercial availability of Lutrepulse has been inconsistent—the product has been discontinued and returned to market multiple times—but compounded gonadorelin from 503B pharmacies has filled the gap, particularly for the TRT co-administration use case that now drives most non-diagnostic gonadorelin prescriptions.

↑ Back to contents

The HPG Axis and GnRH Pulsatility

The hypothalamic-pituitary-gonadal axis is a hierarchical endocrine cascade in which each level regulates the levels below it and receives negative feedback from the hormone output of those lower levels. The hypothalamus secretes GnRH in pulses; the pituitary responds with LH and FSH secretion; the gonads respond with sex steroid and gamete production; sex steroids feed back to suppress hypothalamic GnRH and pituitary gonadotropin secretion, closing the regulatory loop.

The pulsatile nature of GnRH secretion was characterized by Ernst Knobil in the 1970s and 1980s in landmark experiments using hypothalamic-lesioned rhesus monkeys — animals whose GnRH neurons had been surgically destroyed, abolishing reproductive function. Knobil demonstrated that physiological gonadal function could be completely restored by exogenous pulsatile GnRH delivery at the correct frequency, but that continuous GnRH infusion suppressed gonadotropins. This work established that the pattern of GnRH delivery — not just its presence — is the key determinant of pituitary response, and earned Knobil enduring recognition in reproductive biology.

The pulse frequency of GnRH carries encoded information for the pituitary. A slow pulse frequency (approximately 1 pulse per 3–4 hours) preferentially drives FSH secretion; a fast pulse frequency (approximately 1 pulse per 60–90 minutes) preferentially drives LH secretion. This frequency-encoding allows the hypothalamus to differentially regulate LH and FSH output — relevant to the different phases of the menstrual cycle in women and to the differential gonadotropin requirements of spermatogenesis versus Leydig cell testosterone production in men.

---

The Pulse-vs-Continuous Paradox

The phenomenon of GnRH agonist-induced pituitary suppression — where the same molecule that stimulates the pituitary in pulses suppresses it when given continuously — is one of the most clinically exploited pharmacological paradoxes in medicine. The mechanism involves GnRH receptor desensitization and downregulation. When GnRH receptors on pituitary gonadotrophs are continuously occupied by agonist, the cells undergo receptor internalization (reduction in surface receptor number) and uncoupling of the receptor from its downstream G-protein signaling. The result is a refractory state where even high circulating GnRH concentrations fail to stimulate LH and FSH release.

This is why the long-acting GnRH agonists — leuprolide (given monthly or quarterly depot), triptorelin (quarterly depot), and nafarelin (daily nasal spray) — all produce profound gonadotropin suppression and medical castration despite being agonists. They achieve suppression through continuous receptor occupancy, not through antagonism. GnRH antagonists (cetrorelix, ganirelix, degarelix) achieve the same suppressive endpoint through direct receptor blockade, without the initial flare in LH/testosterone that agonists produce before suppression is established.

Gonadorelin, with its 2–4 minute half-life, cannot produce continuous receptor occupancy from a single bolus injection — it is cleared too quickly. Each injection produces a brief pulse, after which receptor occupancy drops near zero and the receptor resensitizes. This is the pharmacological basis for why gonadorelin, unlike the depot GnRH agonists, is stimulatory rather than suppressive — its natural short half-life enforces the pulsatile pattern that physiological stimulation requires.

---

Mechanism of Action

Gonadorelin binds the GnRH receptor (GnRHR) on pituitary gonadotrophs — a Gq/11-coupled GPCR. Agonist binding activates phospholipase C through Gq/11, producing IP3 and DAG. IP3 triggers calcium release from intracellular stores; DAG activates protein kinase C. The combined calcium and PKC signaling drives LH and FSH granule exocytosis and, at longer timescales, upregulates LH and FSH gene transcription. The calcium signal also activates calmodulin-dependent kinases that contribute to the acute secretory response.

The differential LH/FSH response to GnRH pulse frequency operates through distinct intracellular pathways downstream of the receptor. High-frequency pulses activate ERK (extracellular signal-regulated kinase) signaling pathways that preferentially drive LH beta subunit transcription. Low-frequency pulses activate different downstream pathways that favor FSH beta subunit expression. This frequency-decoding mechanism at the gonadotroph level translates the pulsatile pattern of GnRH secretion into differential gonadotropin output — a sophisticated encoding system that is disrupted in conditions of abnormal GnRH pulsatility.

---

Hypogonadotropic Hypogonadism: Restoring the HPG Axis

Hypogonadotropic hypogonadism (HH) is the condition for which gonadorelin is most directly indicated as a therapeutic agent. HH is characterized by low sex hormones (testosterone in men, estrogens in women) in the setting of low or inappropriately normal LH and FSH — a pattern indicating that the problem lies at or above the pituitary (hypothalamic or pituitary level) rather than in the gonads themselves. When HH results from GnRH deficiency specifically — as in Kallmann syndrome (GnRH neuron migration failure), idiopathic hypogonadotropic hypogonadism, hypothalamic amenorrhea, or acquired hypothalamic dysfunction — the gonads are normal and fully capable of responding to gonadotropin stimulation. They simply are not receiving the upstream GnRH signal to drive it.

In these conditions, pulsatile gonadorelin therapy delivered by programmable pump can restore the entire HPG axis to physiological function. The pump delivers small bolus doses (typically 2.5–20 mcg IV or 10–20 mcg SC) every 60–120 minutes, replicating the endogenous pulse pattern. Within days to weeks, LH and FSH rise, gonadal sex hormone production resumes, gonadal volume increases, and spermatogenesis (in men) or ovarian folliculogenesis (in women) can be restored. Published case series and controlled trials demonstrate that pulsatile gonadorelin therapy can achieve fertility in the majority of patients with GnRH-deficiency HH — results that testosterone replacement therapy alone cannot achieve because TRT suppresses, rather than restores, gonadotropin drive.

---

Fertility Induction in Women and Men

In women with hypothalamic amenorrhea — including functional hypothalamic amenorrhea (FHA) caused by excessive exercise, energy deficit, or psychological stress — pulsatile gonadorelin therapy is among the most physiologically appropriate treatments available. FHA involves disruption of the GnRH pulse generator through stress hormones (cortisol, CRH) and metabolic signals (leptin deficiency from low energy availability), resulting in absent or profoundly reduced GnRH pulsatility and consequent anovulation and amenorrhea. Pulsatile gonadorelin restores the GnRH signal directly, bypassing the hypothalamic dysfunction to drive the intact pituitary-ovarian axis below it. Published data show ovulation rates of 70–90% and pregnancy rates of 20–30% per treatment cycle with pulsatile gonadorelin in appropriately selected FHA patients.

In men with HH who desire fertility, pulsatile gonadorelin therapy can restore spermatogenesis and achieve azoospermia reversal in the majority of patients treated for sufficient duration (typically 12–24 months). This is mechanistically superior to TRT for fertility goals: TRT provides testosterone but suppresses spermatogenesis through negative feedback. Pulsatile gonadorelin drives both LH (Leydig cells, testosterone) and FSH (Sertoli cells, spermatogenesis) through the physiological pathway. For men who began TRT without fertility preservation and now wish to father children, transition from TRT to pulsatile gonadorelin (or gonadotropin therapy with hCG + FSH) is the standard approach.

---

Gonadorelin vs hCG During Testosterone Therapy

This is the application that has driven the largest growth in gonadorelin use within the men’s health and TRT community. When exogenous testosterone is administered, hypothalamic GnRH and pituitary LH secretion are suppressed through negative feedback. Without LH signaling, testicular Leydig cells reduce testosterone production, testicular volume decreases (testicular atrophy), and spermatogenesis declines. For men who wish to preserve testicular function, fertility potential, and intratesticular testosterone production during TRT, concurrent administration of a compound that maintains LH-equivalent signaling is necessary.

Historically, hCG (human chorionic gonadotropin) has been the standard choice for this purpose. hCG is an LH analog that directly stimulates Leydig cells through the LH receptor, bypassing the suppressed HPG axis entirely. It is effective at maintaining testicular volume and function during TRT and has decades of clinical use supporting it. However, hCG stimulates only Leydig cells (through LH receptor) — it does not stimulate Sertoli cells or drive FSH release, meaning it provides incomplete spermatogenic support compared to a full HPG axis restoration.

Gonadorelin, delivered in pulses, replaces the hypothalamic GnRH signal that was suppressed by TRT. If pituitary GnRH receptor sensitivity is maintained — which it typically is during TRT, since the suppression is at the hypothalamic level — gonadorelin pulses can drive LH and FSH release from the pituitary, providing both Leydig cell stimulation (testosterone) and Sertoli cell stimulation (spermatogenesis). This is a more complete testicular support than hCG alone. Emerging data from compounding pharmacy prescription records and clinical case series suggest gonadorelin is increasingly replacing hCG for this indication, particularly following FDA supply disruptions that affected compounded hCG availability.

---

Diagnostic Use: GnRH Stimulation Test

A single IV or SC dose of gonadorelin (100 mcg IV is standard for adults; 2.5 mcg/kg for children) provides a reliable test of pituitary gonadotroph reserve and GnRH responsiveness. Blood is drawn for LH and FSH at baseline and at 30 and 60 minutes post-dose. A normal response demonstrates the pituitary’s ability to respond to GnRH stimulation and distinguishes hypothalamic from pituitary causes of hypogonadism. In primary pituitary failure, LH and FSH do not rise despite gonadorelin stimulation. In hypothalamic GnRH deficiency, the pituitary can respond to exogenous GnRH — confirming the deficit is upstream. Extended (multiple-day) pulsatile priming with gonadorelin before the stimulation test can distinguish partial GnRH deficiency from pituitary failure in ambiguous cases.

---

Key Research and Studies

Gonadorelin has one of the longest evidence bases of any compound in this cluster — clinical use in reproductive endocrinology dates to the 1970s, and there are hundreds of published studies covering its use in HH, fertility induction, hypothalamic amenorrhea, and diagnostics. The foundational science from Knobil, Schally (Nobel Prize 1977 for GnRH structure characterization), and Guillemin established the mechanistic framework. Key clinical milestones include demonstration of ovulation induction by pulsatile GnRH in hypothalamic amenorrhea (Leyendecker et al., 1980), restoration of spermatogenesis in GnRH-deficient men (Hoffman and Crowley, 1982), and the long-running Kallmann syndrome pulsatile therapy literature spanning four decades of published case series and cohort studies.

More recent research focuses on the TRT co-administration use case. Bhasin et al. and subsequent groups have characterized the kinetics of HPG axis suppression and recovery with testosterone therapy and the role of LH-pathway maintenance in preserving testicular function. A 2023 analysis of prescription data showed a marked shift in TRT adjunct prescribing toward gonadorelin and away from hCG, reflecting both regulatory changes affecting compounded hCG and growing appreciation of gonadorelin’s more complete HPG axis engagement.

---

Common Claims versus Current Evidence

---

The Human Evidence Landscape

Gonadorelin occupies an unusual position in the Peptidings compound library: it is one of the most thoroughly studied peptides in human clinical medicine. Unlike most compounds covered on this site, the question with gonadorelin is not whether human evidence exists—it is whether the human evidence covers the specific use case driving current community interest.

For its approved clinical indications, the human evidence is robust and decades-deep. Pulsatile gonadorelin for hypothalamic amenorrhea has been studied in multiple controlled trials and case series dating to the early 1980s, with ovulation rates of 70–90% and pregnancy rates of 20–30% per cycle consistently documented. Pulsatile gonadorelin for male hypogonadotropic hypogonadism has published evidence spanning four decades demonstrating restoration of spermatogenesis and fertility. The GnRH stimulation test is one of the most well-validated diagnostic tools in reproductive endocrinology. For a full explanation of how Peptidings categorizes evidence strength, see Evidence Levels Explained.

For the TRT co-administration use case—which is now the primary driver of gonadorelin prescriptions outside formal reproductive endocrinology—the evidence picture is less complete. The mechanistic rationale is solid: pulsatile GnRH should drive pituitary LH and FSH release even when the hypothalamus is suppressed by exogenous testosterone, provided the pituitary gonadotrophs retain GnRH receptor sensitivity. Published clinical data supporting this specific application consists primarily of observational case series, prescription trend analyses, and pharmacokinetic reasoning rather than randomized controlled trials comparing gonadorelin to hCG during TRT. The 2023 shift in prescribing patterns from hCG to gonadorelin was driven partly by FDA regulatory changes affecting compounded hCG availability—not by new efficacy data demonstrating gonadorelin’s superiority.

The critical unanswered question is whether twice-daily subcutaneous gonadorelin injections—the standard community TRT protocol—produce pulsatile signaling that is pharmacologically equivalent to the programmable pump delivery used in the clinical fertility literature. Two injections per day at 12-hour intervals is a different pattern than one pulse every 90 minutes from a pump. The twice-daily protocol is a practical compromise between pharmacological idealism and real-world compliance. It appears to produce measurable LH responses based on community bloodwork reporting, but no controlled trial has directly compared twice-daily SC gonadorelin to continuous pulsatile pump delivery or to hCG for testicular preservation outcomes during TRT.

↑ Back to contents

Safety, Risks, and Limitations

Acute Tolerability

Gonadorelin has an excellent safety profile consistent with its endogenous-equivalent peptide structure and decades of clinical use. The most common adverse events are local injection site reactions (mild redness, brief stinging) with subcutaneous delivery, and rare hypersensitivity reactions. Systemic adverse events are uncommon at physiological pulsatile doses. The compound’s safety record in reproductive endocrinology spans over four decades of clinical use—a depth of safety data that most peptides on Peptidings cannot approach.

Ovarian Hyperstimulation Syndrome (OHSS)

In women undergoing pulsatile gonadorelin therapy for fertility induction, ovarian hyperstimulation syndrome represents the most significant safety concern. OHSS occurs when the ovaries over-respond to gonadotropin stimulation, producing multiple follicles and high estradiol levels. Symptoms range from mild abdominal discomfort and bloating to severe fluid shifts, ascites, and in rare cases, thromboembolic events. This risk is the primary reason pulsatile gonadorelin therapy for fertility requires clinical supervision with regular ultrasound and hormonal monitoring. The risk is lower than with direct gonadotropin injections (hMG, recombinant FSH) because gonadorelin works through the pituitary’s own regulatory mechanisms rather than bypassing them.

Downstream Hormonal Effects

The most important safety consideration for TRT co-administration is not direct gonadorelin toxicity but the downstream hormonal consequences of maintained LH and FSH output. In men, maintained LH-driven testosterone production adds to the exogenous testosterone from TRT—potentially increasing total testosterone and estradiol levels beyond intended therapeutic targets. Estradiol elevation from aromatization of the additional intratesticular testosterone may produce symptoms including water retention, mood changes, and gynecomastia risk. Regular bloodwork monitoring (total testosterone, free testosterone, estradiol, LH, FSH) is essential during combined gonadorelin + TRT protocols.

Injection-Related Risks

Subcutaneous injection carries inherent user-technique-dependent risks: injection site infection, lipodystrophy with repeated use at the same site, and risks from non-sterile technique. For TRT co-administration protocols requiring twice-daily injection, site rotation is particularly important to prevent local tissue changes. Use of non-pharmaceutical-grade product supply adds contamination and potency uncertainty risks.

Anti-GnRH Antibody Formation

Rare cases of anti-GnRH antibody formation have been reported with prolonged pulsatile gonadorelin therapy, particularly in patients treated for months to years. Antibody formation can reduce gonadorelin’s effectiveness over time. This is primarily a concern for long-term clinical pulsatile pump therapy rather than twice-daily SC injection protocols, but it represents a theoretical consideration for any long-duration gonadorelin use.

↑ Back to contents

Legal and Regulatory Status

Gonadorelin (Factrel) is FDA-approved in the United States for evaluation of hypothalamic-pituitary gonadotropic function and for induction of ovulation in patients with primary hypothalamic amenorrhea (pulsatile pump delivery, Lutrepulse). It is a prescription medication. Compounded gonadorelin from 503B pharmacies is widely used for TRT co-administration and fertility protocols. WADA: not prohibited.

---

Research Protocols and Laboratory Practices

Reconstitution

Gonadorelin is typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water for injection. Inject bacteriostatic water slowly along the inside vial wall—not directly onto the powder cake—and allow it to dissolve without agitation. Swirl gently if needed; never shake. Calculate the resulting concentration before drawing any dose, and verify before each injection. For detailed reconstitution instructions, see the Reconstitution Guide.

Storage

Lyophilized powder: store at 2–8°C (35–46°F), protected from light. Shelf life varies by manufacturer but is typically 2–3 years when properly stored. After reconstitution with bacteriostatic water: refrigerate at 2–8°C (35–46°F) and use within 28 days. Do not freeze reconstituted solutions—freezing causes aggregation and activity loss. Note the reconstitution date on the vial. For comprehensive storage guidance, see the Peptide Storage and Handling Guide.

Administration Route

Subcutaneous injection is the standard route for TRT co-administration protocols. Acceptable injection sites include the abdomen (lateral to umbilicus), anterior or lateral thigh, and outer upper arm. Rotate injection sites to prevent lipodystrophy. Standard needle: 27–31 gauge, 8–12 mm length, at 45–90 degrees depending on tissue thickness. For clinical pulsatile pump delivery, either IV or SC routes are used depending on the clinical protocol. For injection technique and site rotation guidance, see the Subcutaneous Injection Technique Guide.

↑ Back to contents

Dosing in Published Research

The following table summarizes published clinical dosing protocols for gonadorelin across its major indications. Unlike many compounds on Peptidings, gonadorelin has extensive human dosing data from decades of clinical use. For background on why half-life determines dosing frequency, see Half-Lives and Dosing Intervals.

Study / Source	Population	Dose	Route	Frequency	Duration	Key Findings
GnRH Stimulation Test (standard diagnostic)	Adults with suspected hypogonadism	100 mcg	IV bolus	Single dose	Acute (0, 30, 60 min draws)	Distinguishes hypothalamic from pituitary hypogonadism; normal = LH rise ≥2–3× baseline
Leyendecker et al., Arch Gynecol, 1980	Women with hypothalamic amenorrhea	5–20 mcg per pulse	IV pulsatile pump	Every 90 min	Until ovulation (10–14 days)	Ovulation induction demonstrated; pregnancy rates 20–30% per cycle
Hoffman & Crowley, NEJM, 1982	Men with idiopathic HH	25–600 ng/kg per pulse	SC/IV pulsatile pump	Every 120 min	12–24 months	Spermatogenesis restored; testosterone normalized; fertility achieved in majority
Kallmann syndrome case series (multiple)	GnRH neuron migration failure patients	5–20 mcg per pulse	SC pulsatile pump	Every 90–120 min	Months to years	Full HPG axis restoration; gonadal function normalized
Lutrepulse (FDA-approved protocol)	Women with primary hypothalamic amenorrhea	5 mcg per pulse (starting)	IV pulsatile pump	Every 90 min	21 days per cycle	FDA-approved; ovulation rate ~90% in appropriately selected patients

↑ Back to contents

Dosing in Independent Self-Experimentation Communities

Community protocols for gonadorelin have stabilized around conventions driven by the TRT co-administration use case. The following describes what is conventionally used; it is not a dosing recommendation, and the clinical pump-based protocols above represent the stronger evidence base. For context on why more frequent dosing does not always produce proportionally better results, see More Is Not Always More: The Dose-Response Plateau.

Protocol Parameter	Typical Community Range	Notes
Dose per injection	100–200 mcg SC	Most common reference dose is 100 mcg. Some practitioners prescribe 200 mcg. Higher doses have not been shown to produce proportionally greater LH response.
Frequency	Twice daily (every 12 hours)	Compromise between pharmacological idealism (every 90 min) and real-world compliance. Some practitioners use 3× weekly. Twice daily is the most common community standard.
Timing	Morning and evening	Spaced approximately 12 hours apart to simulate pulsatile delivery. Some protocols specify upon waking and before bed.
Primary use context	TRT co-administration	Maintaining testicular function, size, and fertility potential during exogenous testosterone therapy. Increasingly used in place of hCG.
Cycle length	Concurrent with TRT (ongoing)	Unlike GH secretagogues, gonadorelin is typically used continuously alongside TRT rather than cycled. The rationale: testicular suppression from TRT is ongoing, so gonadorelin support must be ongoing.
Reconstitution	Per pharmacy instructions	Compounded gonadorelin from 503B pharmacies typically comes with specific reconstitution instructions. Store reconstituted vials at 2–8°C (35–46°F). Use within 28 days.

↑ Back to contents

Frequently Asked Questions

Related Compounds: How Gonadorelin Compares

Gonadorelin is the physiological GnRH — the upstream master regulator from which all other GnRH-based drugs derive. Its closest relatives in this cluster are leuprolide, triptorelin, and nafarelin — all synthetic GnRH agonists that exploit the continuous-suppression pathway that gonadorelin avoids by virtue of its short half-life. Understanding gonadorelin requires understanding how it differs from those suppressants. Kisspeptin, the compound upstream of GnRH in the hypothalamic hierarchy, is the other closely related article in this cluster. The table below shows all compounds in the Sexual Health & Hormonal cluster.

---

Edit

Compound	Mechanism Class	Primary Target / Action	Evidence Tier	FDA Approval Status	WADA Status	Primary Route(s)	Key Indication(s)	Peptidings Article
PT-141 (Bremelanotide)	Melanocortin receptor agonist — MC3R / MC4R	Central nervous system — activates desire pathways in hypothalamus; distinct from PDE5 vascular mechanism	Approved Drug	FDA-approved 2019 as Vyleesi — HSDD in premenopausal women; off-label in men for ED	Not prohibited	SC injection (approved); intranasal (off-label)	Hypoactive sexual desire disorder (HSDD) in women; erectile dysfunction (off-label)	peptidings.com/peptides/pt-141/
Kisspeptin	Neuropeptide — GPR54 / Kiss1R agonist	Hypothalamic GnRH neurons — master upstream regulator of HPG axis; controls sex hormone production	Clinical Trials	Not FDA-approved; active Phase I/II investigations	Not prohibited	IV infusion (research); SC injection (investigational)	Hypothalamic amenorrhea; infertility; disrupted GnRH signaling; sexual motivation research	peptidings.com/peptides/kisspeptin/
Gonadorelin	GnRH receptor agonist (pulsatile = stimulation)	Pituitary gonadotrophs — stimulates LH and FSH release when delivered in physiological pulses	Approved Drug	FDA-approved for hypogonadism diagnosis and fertility induction	Not prohibited	IV / SC injection; pulsatile pump delivery	Male hypogonadism; fertility induction; hypothalamic amenorrhea	peptidings.com/peptides/gonadorelin/
Leuprolide	GnRH receptor agonist (continuous = suppression)	Pituitary gonadotrophs — continuous stimulation causes receptor downregulation and sex hormone suppression	Approved Drug	FDA-approved (Lupron and others) — prostate cancer, endometriosis, precocious puberty, gender-affirming care	Not prohibited	SC injection; IM injection; depot formulations	Prostate cancer; endometriosis; uterine fibroids; central precocious puberty; gender-affirming hormone therapy	peptidings.com/peptides/leuprolide/
Triptorelin	GnRH receptor agonist (continuous = suppression)	Pituitary gonadotrophs — same paradoxical suppression mechanism as leuprolide	Approved Drug	FDA-approved (Trelstar) — prostate cancer; investigational for precocious puberty	Not prohibited	IM depot injection	Prostate cancer; central precocious puberty; some endometriosis applications	peptidings.com/peptides/triptorelin/
Nafarelin	GnRH receptor agonist (continuous = suppression)	Pituitary gonadotrophs — intranasal delivery achieves systemic GnRH agonist effect	Approved Drug	FDA-approved (Synarel) — endometriosis; central precocious puberty	Not prohibited	Intranasal spray	Endometriosis; central precocious puberty	peptidings.com/peptides/nafarelin/
Oxytocin	Neuropeptide — oxytocin receptor (OTR) agonist	Uterine and breast smooth muscle (approved); CNS — bonding, sexual arousal, orgasm facilitation (investigational)	Approved Drug	FDA-approved (Pitocin) for labor induction and postpartum hemorrhage — sexual/bonding indications investigational	Not prohibited	IV infusion (approved obstetric); intranasal (investigational)	Labor induction; postpartum hemorrhage (approved); sexual arousal enhancement; social bonding (investigational)	peptidings.com/peptides/oxytocin/
Relaxin	Relaxin receptor agonist — RXFP1 / RXFP2	Vascular smooth muscle and connective tissue — vasodilation, tissue remodeling, increased genital blood flow	Clinical Trials	Not FDA-approved for sexual indications; serelaxin (Novartis) investigated for acute heart failure	Not prohibited	SC injection; IV infusion (research)	Female sexual arousal disorder; connective tissue remodeling; investigational cardiovascular	peptidings.com/peptides/relaxin/

Summary and Key Takeaways

• Gonadorelin is synthetic GnRH — identical in sequence to the endogenous hypothalamic decapeptide that drives the entire HPG axis. Its 2–4 minute half-life means single SC injections produce brief pulses that stimulate, not suppress, gonadotropin release.
• The pulse-vs-continuous paradox is foundational: pulsatile gonadorelin stimulates LH and FSH; continuous GnRH receptor occupancy suppresses them. This is why gonadorelin is therapeutically opposite to leuprolide, triptorelin, and nafarelin despite sharing the same receptor.
• Clinical indications: hypogonadotropic hypogonadism (restoring HPG axis when GnRH is deficient); fertility induction in women with hypothalamic amenorrhea; fertility induction in men with HH; GnRH stimulation testing for pituitary reserve.
• TRT co-administration: growing use as an hCG alternative to maintain testicular function and fertility potential during testosterone therapy. More complete HPG engagement (LH + FSH) than hCG (LH only), but requires more frequent dosing (typically twice daily).
• Safety: excellent profile — endogenous peptide, local injection site reactions, no significant systemic toxicity. Monitor for OHSS in women undergoing fertility protocols.
• FDA approved (Factrel, Lutrepulse). Compounded formulations widely used. WADA: not prohibited. Requires physician supervision.

Selected References and Key Studies

1. Knobil E. The neuroendocrine control of the menstrual cycle. Recent Prog Horm Res. 1980;36:53–88. PMID 6999069 — foundational pulsatile GnRH physiology
2. Schally AV, et al. Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science. 1971;173(4001):1036–8. PMID 4938639 — Nobel Prize-recognized characterization of GnRH structure
3. Leyendecker G, et al. Induction of ovulation with chronic intermittent (pulsatile) administration of GnRH in women with hypothalamic and hyperprolactinaemic amenorrhea. Arch Gynecol. 1980;229(3):177–90. PMID 6996003
4. Hoffman AR, Crowley WF Jr. Induction of puberty in men by long-term pulsatile administration of low-dose gonadotropin-releasing hormone. N Engl J Med. 1982;307(20):1237–41. PMID 6750657
5. Pitteloud N, et al. Reversibility of gonadotropin deficiency in men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2005;90(3):1426–32. PMID 15598680
6. Barbonetti A, et al. Low testosterone and mortality: a systematic review and meta-analysis. J Sex Med. 2023 — context for TRT and HPG axis management

---

Further Reading and References

• Sexual Health & Hormonal Research Cluster — Peptidings.com
• Kisspeptin: Research Overview — Peptidings.com — the neuropeptide upstream of GnRH
• Leuprolide: Research Overview — Peptidings.com — the continuous-suppression counterpart
• Evidence Levels Explained — Peptidings.com
• PubMed: Gonadorelin Pulsatile Therapy Research